Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 2;9(6):1686.
doi: 10.3390/jcm9061686.

Long-Term Prognosis of Patients with Myocardial Infarction Type 1 and Type 2 with and without Involvement of Coronary Vasospasm

Affiliations

Long-Term Prognosis of Patients with Myocardial Infarction Type 1 and Type 2 with and without Involvement of Coronary Vasospasm

Ryota Sato et al. J Clin Med. .

Abstract

While prognoses in relation to myocardial infarction (MI) type have been elucidated in past reports, the results were not consistent, perhaps due to occurrence of Type 2 MI with CVS and its mortality. The Japanese registry of acute Myocardial Infarction diagnosed by Universal Definition (J-MINUET) is a prospective multicenter registry in Japan. In contrast to thromboembolic event-related Type 1 myocardial infarction (MI), clinical features of Type 2 MI, including coronary vasospasm (CVS), are varied due to the heterogeneous nature of its development. To elucidate the MI type-related all-cause mortality, 2989 consecutive patients with AMI were stratified as Type 1 MI, Type 2 MI with CVS, and Type 2 MI with non-CVS. Most patients (n = 2834; 94.8%) were classified as Type 1 MI and 155 patients (5.2%) were classified as Type 2 MI. Of the Type 2 MI patients, 87 (56% of Type 2 MI) were diagnosed as MI with CVS. Although the 3-year mortality was comparable between Type 1 and Type 2 MI patients, significant differences were observed between Type 2 MI with CVS and with non-CVS (3.4% and 22.1%, p < 0.001). Among Japanese patients with AMI, mortality rates between Type 1 MI and Type 2 MI are comparable, but further stratification of Type 2 MI (with or without CVS) may be useful in predicting the prognosis of patients with Type 2 MI.

Keywords: acute myocardial infarction; clinical outcomes; coronary vasospasm; universal definition of myocardial infarction.

PubMed Disclaimer

Conflict of interest statement

K.S. (Kenji Sakamoto) has received a research grant from Daiichi Sankyo Co., Ltd. K.K. (Koichi Kaikita) has received several research grants from Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., Novartis Pharma K.K., and SBI Pharma K.K. K.T. (Kenichi Tsujita) has received honoraria from Amgen Astellas Bio Pharma K.K., Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., MSD K.K., Sanofi K.K., and has received several research grants from AstraZeneca K.K., Astellas Pharma Inc., Bayer Yakuhin, Ltd., Boehringer Ingelheim Japan., Boston Scientific Japan K.K., Chugai Pharmaceutical Co, Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Kowa Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., MSD K.K., Pfizer Japan Inc., Sanofi K.K., Shionogi & Co., Ltd., and Takeda Pharmaceutical Co., Ltd. Y.O. has received several research grants from Bayer Yakuhin, Ltd., Research Institute for Production Development, Daiichi-Sankyo Co., Ltd., and Dainippon Sumitomo Co., Ltd. K.K. (Kazuo Kimura) has received honoraria from Astrazeneca, Toa Eiyo Ltd., MSD K.K., Bayer Yakuhin, Ltd., Daiichi-Sankyo Co., Ltd. and has received several research grants from MSD K.K., Daiichi-Sankyo Co., Ltd., Ono Pharmaceutical Co., Pfizer Japan Inc., Bayer Yakuhin Ltd., Takeda Pharmaceutical Co., Ltd., Boehringer Ingelheim Japan, Tanabe Mitsubishi, and Astellas Pharma Inc. W.S. has received honoraria from Daiichi-Sankyo Co., Ltd., Boehringer Ingelheim Japan, Bayer Yakuhin Ltd., Bristole, Ono Pharmaceutical Co., and received several research grants from Daiichi-Sankyo Co., Ltd., Boehringer Ingelheim Japan, Ono Pharmaceutical Co., Otsuka Pharmaceutical Co., Eisai Co., Mitsubishi Tanabe Pharma Co., Asterllas Pharma Inc., and St Jude Medical. Y.S. (Yoshihiko Saito) has received honoraria from Otsuka Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Novartis Pharma K.K. and received several research grants from Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd., Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Eisai Co., Ltd., ZERIA Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., and Boston Scientific Japan K.K. T.M. (Toshiaki Mano) has received a research grant from Abbot Vascular Japan. K.T. (Kengo Tanabe) has received honoraria from Abbot vascular Japan, Mitsubishi Tanabe Pharma Co., Daiichi Sankyo Co., Ltd. and has received several research grants from Kaneka and Terumo. M.I. has received honoraria from Bayer Yakuhin Ltd., MSD K.K., Astra Zeneca, Astellas Pharma Inc. and has received several research grants from Abbott Vascular Japan, Boston Scientific Japan K.K., Sanofi K.K., MSD K.K., Astellas Pharma Inc., Bayer Yakuhin Ltd., Pfizer, Daiichi Sankyo Co., Ltd., MID, and Goodman. No funders have any role in this study.

Figures

Figure 1
Figure 1
Flowchart of the current study. MI, myocardial infarction; CVS, coronary vasospasm.
Figure 2
Figure 2
Kaplan–Meier estimates of all-cause mortality between Type 1 MI and Type 2 MI (A) and Table 2. MI is stratified into two groups (B) over a 3-year period.
Figure 3
Figure 3
Event rates and Kaplan–Meier estimates of all-cause mortality at 1year period. (Upper) All-cause mortality between Type 1 MI and Type 2 MI (A) and the mortality among the 3 groups, when Type 2 MI is stratified into 2 groups (B) within 1-year period. (Lower) Kaplan–Meier estimates of all-cause mortality between Type 1 MI and Type 2 MI (C) and the mortality among the three groups, when Type 2 MI is stratified into two groups (D) within 1-year period.

Similar articles

Cited by

References

    1. The Joint European Society of Cardiology/American College of Cardiology Committee Myocardial infarction redefined—A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur. Heart J. 2000;21:1502–1513. doi: 10.1053/euhj.2000.2305. - DOI - PubMed
    1. Thygesen K., Alpert J.S., White H.D. Universal definition of myocardial infarction. Eur. Heart J. 2007;28:2525–2538. - PubMed
    1. Thygesen K., Alpert J.S., Jaffe A.S., Simoons M.L., Chaitman B.R., White H.D., Writing Group on the Joint, ESC/ACCF/AHA/WHF Third universal definition of myocardial infarction. Eur. Heart J. 2012;33:2551–2567. doi: 10.1093/eurheartj/ehs184. - DOI - PubMed
    1. Thygesen K., Alpert J.S., Jaffe A.S., Chaitman B.R., Bax J.J., Morrow D.A., White H.D., Executive Group on behalf of the Joint European Society of Cardiology /American College of Cardiology /American Heart Association /World Heart Federation Task Force for the Universal Definition of Myocardial, I. Fourth universal definition of myocardial infarction (2018) Eur. Heart J. 2018;40:237–269. doi: 10.1093/eurheartj/ehy462. - DOI - PubMed
    1. Boeddinghaus J., Twerenbold R., Nestelberger T., APACE Investigators Clinical validation of a novel high-sensitivity cardiac troponin I assay for early diagnosis of acute myocardial infarction. Clin. Chem. 2018;64:1347–1360. doi: 10.1373/clinchem.2018.286906. - DOI - PubMed

LinkOut - more resources